Japan has been working feverishly to stay at the cutting edge of research and clinical applications in regenerative medicine. It has invested billions of yen in induced pluripotent stem (iPS) cells — made by reprogramming an individual’s adult cells so that they can develop into any body tissue — and has overhauled its drug regulations to create a fast track to bring regenerative therapies to market.